Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Oligodendroglioma 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Multiple Myeloma 1Melanoma 1Liposarcoma, Myxoid 1Liposarcoma 1Glioma 1Ganglioneuroma 1Ganglioglioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1Advanced Solid Tumor 1

Interventions

Oxaliplatin 16Irinotecan 12Fluorouracil 12Leucovorin 10Bevacizumab 8pembrolizumab 7Cetuximab 7Capecitabine 7Nivolumab 5Gemcitabine 5Cyclophosphamide 5fludarabine 4aldesleukin 4Panitumumab 4Folfox protocol 4oblimersen 3Interleukin-2 3selpercatinib 2poly ICLC 2labetuzumab 2dehydroftorafur 2conatumumab 2cemiplimab 2bintrafusp alfa protein, human 2Tomography, X-Ray Computed 2Specimen Handling 2Receptor Protein-Tyrosine Kinases 2Radiotherapy 2Levoleucovorin 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colonic Neoplasms × mirdametinib × Clear all
NCT00147550 2013-09-13

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Pfizer

Phase 1/2 Terminated
79 enrolled
BreastDermatologicGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡